title: Cefotetan compared with gentamicin and tinidazole in acute abdominal surgery.
abstract: In a prospective randomised trial 190 consecutive admissions undergoing emergency abdominal surgery were allocated to receive a 24-h peri-operative prophylactic regime of either cefotetan or gentamicin and tinidazole. Wound sepsis developed in 14 patients in each group and one patient in each group developed intra-abdominal abscess. Nine patients in the cefotetan group and 10 patients in the gentamicin and tinidazole group died within 1 month of surgery. The death of one patient in each group was directly related to sepsis. Sixty-five per cent of aerobes isolated at operation were sensitive to cefotetan and 62% sensitive to gentamicin. The in vitro anaerobic cover of tinidazole was complete, whereas 13% of anaerobes isolated at operation were resistant to cefotetan. Anaerobes, predominantly Bacteroides fragilis, were isolated from six of the 14 infected wounds following cefotetan prophylaxis and two of the 14 infected wounds in the gentamicin and tinidazole group. It is therefore recommended that cefotetan should be combined with a nitroimidazole in patients undergoing emergency colo-rectal procedures.
authors.forename: A G
authors.initials: AG
authors.lastname: Tanner
authors.forename: B T
authors.initials: BT
authors.lastname: Thom
authors.forename: C J
authors.initials: CJ
authors.lastname: Strachan
mesh_terms: D000006:Abdomen, Acute / Q000601:surgery*; D001420:Bacteria, Aerobic / Q000302:isolation & purification; D001421:Bacteria, Anaerobic / Q000302:isolation & purification; D001437:Bacteriuria / Q000382:microbiology; D015313:Cefotetan; D002513:Cephamycins / Q000009:adverse effects / Q000627:therapeutic use*; D013293:Enterococcus faecalis / Q000302:isolation & purification; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009593:Nitroimidazoles / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation; D018805:Sepsis / Q000382:microbiology; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D014011:Tinidazole / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D002513:Cephamycins; D005839:Gentamicins; D009593:Nitroimidazoles; D014011:Tinidazole; D015313:Cefotetan